NCT06533748 - Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2034

Conditions

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma

Interventions

DRUG

Dexamethasone

Given orally (PO) or intravenously (IV).

DRUG

Vincristine

Given IV.

DRUG

Inotuzumab

Given IV.

DRUG

Blinatumomab

Given IV.

DRUG

Dasatinib

Given PO.

PROCEDURE

IT MHA

Given Intrathecal (IT), Age adjusted.

DRUG

Cyclophosphamide

Given IV.

DRUG

Cytarabine

Given IV or IT.

DRUG

Methotrexate

Given IT, IV, PO or intramuscular (IM).

DRUG

6-Mercaptopurine

Given PO.

DRUG

Calaspargase

Given IV.

DRUG

Daunorubicin

Given IV.

DRUG

Thioguanine

Given PO (participants intolerant to mercaptopurine).

Trial Locations (2)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

74136

RECRUITING

Saint Francis Children's Hospital, Tulsa